The UK medicines agency, the MHRA, says it is planning to increase the role of patients in its scientific assessments by boosting their input at the pre-authorization stage, possibly in cases such as the submission of a new active substance, a new indication of an existing drug, or a combination product.
It is also proposing to boost patient input in cases where more information is needed, such as assessments for conditional...